Encouraging news from GSK, particularly the express acknowledgements relating to the UK's leading role in life sciences, the educated and talented skills base and the beneficial tax rates and other incentives the UK has to offer (which reflect many of my comments immediately post-Brexit in my article "Ich bin ein Berliner").

Let's now just hope that, whatever happens over the next few years, UK life sciences manage to retain the level of investment it needs (both privately and by way of government backed incentives, to shore up the potential gap in funding that will exist if the UK does in fact leave the EU (thereby resulting in the UK life sciences sector being ineligible for EU funding)) to ensure it keeps its place at the table as one of the world's leading life science centres.

Quote mark icon

GlaxoSmithKline is to invest £275m to expand its UK manufacturing sites, saying the country remains "an attractive location" despite Brexit.The pharmaceutical firm, whose chief executive Andrew Witty backed the Remain campaign, said the UK's skilled workforce and competitive tax system helped drive the decision.It said most of the products made at the expanded sites would be exported.The firm said it expected its investment to create new jobs.
featured image